Keywords Respiratory syncytial virus Vaccination Immunisation Public health Evidence before this study In 2023, a large multinational phase 3 clinical trial demonstrated that the bivalent prefusion F (RSVpreF) vaccine (Abrysvo®, Pfizer) was safe and effective in preventing RSV-associated lower respiratory tract infection in older adults.
Simon Cottrell
As seen in:
National Institutes of Health,
Wiley Online Library,
Bandcamp Daily,
Elsevier,
MDPI,
The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Simon
Contact Simon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack